A61K9/7007

LIPOPHILIC ACTIVE ORAL FILM FORMULATION AND METHOD OF MAKING THE SAME

Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive logP. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.

FILM PREPARATION

The present invention addresses the problem of providing a film preparation that enables large quantities of medicinal products to be blended thereinto. The present invention provides a film preparation that contains a film base material, which contains a water-soluble polymer, and medicinal product containing particles, which are supported on the film base material and which have a coating layer containing a hydrophobic coating agent on the outermost surface of the particles. The content of the medicinal product in the medicinal product-containing particles may be 0.1-95 mass % relative to the overall film preparation. The water-soluble polymer may include one or more types selected from the group consisting of hydroxypropyl cellulose, hydroxypropylmethyl cellulose and pullulan.

PALONOSETRON ORAL TRANSMUCOSAL FILM OR PATCH
20170367969 · 2017-12-28 ·

The present invention provides a pharmaceutical composition for delivering palonosetron through the buccal mucosa or sublingual mucosa. The pharmaceutical composition comprises 0.05-35% (w/w) of palonosetron, 40-90% of a film forming agent, 1-10% (w/w) of a plasticizer, 5-25% (w/v) of an adhesive agent, and 0.1-5% of a penetration enhancing agent. A preferred plasticizer is a polysorbate. A preferred adhesive agent is polyvinylpyrrolidone or carboxymethylcellulose. A preferred penetration enhancing agent is peppermint oil or menthol.

Formulations and Methods of Treatment for Treating Nail Fungal Infections
20170367972 · 2017-12-28 ·

The present invention relates to methods and compositions for the treatment of infections of the nails, in particular the treatment of onychomycosis.

DISSOLVABLE MEDICAL DEVICE FOR DRUGS DELIVERY
20230201030 · 2023-06-29 ·

A dissolvable medical device for placing on the outer exposed surface of the eye to deliver a drug to the eye comprising: a polymeric film has sufficient dimensions to substantially cover a cornea when applied to an eye, wherein the polymeric film comprising one or more mucoadhesive polymers. The polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive and the pharmaceutically active agents after applying the polymeric film to the eye. The dissolved polymeric film is not impeding visualization of ocular tissue while maintaining a protective film on outer surface of the eye.

Medicinal skin protection composition with an active ingredient combination which improves the skin barrier

A medicinal skin protection composition is disclosed with an active ingredient combination that specifically serves to care for aging skin that is exposed to difficult environmental conditions. The active ingredient combination obligatorily includes the components almond oil, linseed oil fatty acids, amino acids, and creatine. The medicinal skin protection composition can be used for aging skin in the form of creams, lotions etc., and also for a variety of incontinence articles, such as sanitary towels or nappies.

Wafer and capsule formulations with enhanced dissolution rates for fenofibrate

The invention relates to developing a novel water and capsule formulation using fenofibrate which is difficult to dissolve and control its release rate in vitro. For example, the invention relates to the creation of capsules and wafers comprising: fenofibrate, a surfactant, a carrier wax, a film former, a plasticizer, and optionally a super disintegrant or other ingredients. The invention further relates to the process of forming such capsules and wafers.

USE OF CLOSTRIDIUM HISTOLYTICUM PROTEASE MIXTURE IN PROMOTING WOUND HEALING
20170360904 · 2017-12-21 · ·

Provided are methods for repairing a wound or inducing the proliferative phase of a wound comprising administering a composition comprising a protease mixture comprising collagenases and a neutral protease to the wound in an amount effective for repair of wound tissue or for inducing the proliferative phase in the wound.

Composition comprising amino acid polymers and a bioactive agent and method of preparing thereof

A method of treating, reducing or preventing bacterial infection in a wound, the method comprising: applying a film on the wound, the film including a biodegradable polymer with bacteriophages dispersed therein, wherein the polymer is a poly (ester amide urea).

Nanowire-Coated Microdevice and Method of Making and Using the Same

A microdevice containing a plurality of nanowires on a biocompatible surface, and methods of making and using the same are provided. Aspects of the present disclosure include forming a plurality of microdevices on a substrate where each microdevice includes a plurality of nanowires. The nanowires may be loaded with an active agent by disposing the active agent onto the surface of the nanowires. Also provided herein are kits that include the subject microdevices.